Atrial Fibrillation

Area of Science:

• Cardiology
• Internal Medicine
• Clinical Practice

Background:

• The clinical landscape for atrial fibrillation (AF) diagnosis and treatment has evolved significantly since 2017.
• Direct oral anticoagulants (DOACs) are now the primary treatment for thromboembolic disease.
• Antidotes for DOACs are readily available, enhancing safety.

Purpose of the Study:

• To provide an updated overview of current evidence and clinical practice for atrial fibrillation.
• To highlight advancements in anticoagulation, device-based therapies, and rhythm control.
• To emphasize the importance of managing AF risk factors.

Main Methods:

• Review of recent scientific literature and clinical guidelines.
• Synthesis of evidence regarding pharmacological and interventional treatments for AF.
• Emphasis on risk factor modification for AF prevention.

Main Results:

• DOACs are the predominant anticoagulation therapy, with available antidotes.
• Left atrial appendage occlusion is a common alternative for patients intolerant to anticoagulation.
• Early rhythm control and catheter ablation are increasingly utilized for AF management.
• Management of hypertension, diabetes, and obesity is critical for AF prevention.

Conclusions:

• Current evidence supports expanded therapeutic options for AF, including novel anticoagulants and interventional procedures.
• Early rhythm control and risk factor management are key components of comprehensive AF care.
• The approach to AF treatment has shifted towards more proactive and individualized strategies.